What is the recommended dose of racecadotril (acetorphan) for children with acute diarrhea?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Racecadotril Dosing in Children

Racecadotril is dosed at 1.5 mg/kg orally three times daily (every 8 hours) in children aged 3 months and older with acute diarrhea, administered as adjunctive therapy to oral rehydration solution. 1, 2

Standard Dosing Protocol

  • Administer 1.5 mg/kg orally every 8 hours (three times daily) for children 3 months to 5 years of age with acute watery diarrhea 1, 2
  • Continue treatment until diarrhea resolves, typically within 28-72 hours based on clinical trials 2
  • Always use racecadotril as an adjunct to oral rehydration therapy, never as monotherapy 1, 2

Clinical Context and Availability

  • Racecadotril is NOT available in North America (United States and Canada), limiting its use to other regions where it is approved 3
  • The drug reduces stool output by approximately 46-50% compared to placebo when added to oral rehydration therapy 1, 2
  • It works as an enkephalinase inhibitor with antisecretory properties, reducing intestinal hypersecretion without affecting gut motility 2

Evidence Quality and Efficacy

The dosing recommendation of 1.5 mg/kg three times daily is based on multiple randomized controlled trials demonstrating:

  • Significant reduction in 48-hour stool output (92 g/kg vs 170 g/kg with placebo, p<0.001) 2
  • Shorter duration of diarrhea (median 28 hours vs 72 hours with placebo) 2
  • Reduced need for oral rehydration solution intake 2
  • Good tolerability with only mild, transient adverse effects 1, 2

However, a 2019 Cochrane systematic review concluded that racecadotril has little benefit in improving acute diarrhea outcomes and does not support routine use outside of research settings 4. This creates a discrepancy between older individual trials showing benefit and more recent comprehensive meta-analysis showing limited clinical impact.

Safety Profile

  • Tolerability is comparable to placebo (10.4% vs 10.6% adverse event incidence) 5
  • Adverse events when present are typically mild and transient 1, 2
  • No serious safety concerns have been identified in pediatric populations 1, 2, 5

Important Caveats

  • This medication is distinct from antimotility drugs like loperamide, which are absolutely contraindicated in all children under 18 years of age 3, 6
  • Racecadotril works through antisecretory mechanisms rather than slowing gut motility, making it theoretically safer than loperamide 2
  • Despite demonstrated reductions in stool output, the clinical significance remains debated given the Cochrane review findings 4
  • Geographic availability severely limits practical application of this dosing information for North American practitioners 3

References

Research

Racecadotril in the treatment of acute watery diarrhea in children.

The New England journal of medicine, 2000

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Racecadotril for acute diarrhoea in children.

The Cochrane database of systematic reviews, 2019

Guideline

Management of Diarrhea in Children

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.